GILEAD SCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
GILEAD SCIENCES, INC. (GILD) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $0 as of 2013-12-31, per its 10-K filed 2014-02-25.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2014-02-25
- 2013-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $0.00.
- 2012-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $0.00.
- 2012-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $0.00.
- 2012-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $43.87M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value |
|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-02-25 |
| 2012-12-31 | $0.00 10-K · filed 2014-02-25 |
| 2012-09-30 | $0.00 10-Q · filed 2012-11-06 |
| 2012-06-30 | $43.87M 10-Q · filed 2012-11-06 |
| 2012-03-31 | $48.17M 10-Q · filed 2012-08-01 |
| 2011-12-31 | $71.69M 10-K · filed 2014-02-25 |
| 2011-09-30 | $81.82M 10-Q · filed 2012-11-06 |
| 2011-06-30 | $104.14M 10-Q · filed 2012-11-06 |
| 2011-03-31 | $116.82M 10-Q · filed 2012-08-01 |
| 2010-12-31 | $80.36M 10-K · filed 2013-02-27 |
| 2010-09-30 | $88.31M 10-Q · filed 2011-11-04 |
| 2010-06-30 | $94.06M 10-Q · filed 2011-11-04 |
| 2010-03-31 | $105.59M 10-Q · filed 2011-08-05 |
| 2009-12-31 | $105.66M 10-K · filed 2012-02-23 |
| 2009-06-30 | $102.90M 10-Q · filed 2010-08-09 |
| 2009-03-31 | $102.59M 10-Q · filed 2010-08-09 |
| 2008-12-31 | $102.63M 10-Q · filed 2010-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |